H. Lundbeck A/S (OTCMKTS:HLUYY) has been assigned a consensus recommendation of “Hold” from the eight research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have given a buy recommendation to the company.
Several equities research analysts have issued reports on HLUYY shares. Barclays reiterated an “overweight” rating on shares of H. Lundbeck A/S in a research note on Tuesday, October 13th. ValuEngine raised H. Lundbeck A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, December 1st. Zacks Investment Research raised H. Lundbeck A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, January 6th. Credit Suisse Group reaffirmed an “underperform” rating on shares of H. Lundbeck A/S in a research report on Wednesday, November 4th. Finally, UBS Group reissued a “buy” rating on shares of H. Lundbeck A/S in a report on Friday, November 6th.
Shares of HLUYY stock opened at $34.86 on Thursday. The company’s fifty day simple moving average is $33.29 and its 200-day simple moving average is $33.50. The company has a quick ratio of 0.80, a current ratio of 1.10 and a debt-to-equity ratio of 0.77. The firm has a market cap of $6.94 billion, a PE ratio of 27.23 and a beta of 0.68. H. Lundbeck A/S has a 12 month low of $25.68 and a 12 month high of $44.60.
H. Lundbeck A/S Company Profile
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia.
Further Reading: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for H. Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.